StocksFundsScreenerSectorsWatchlists
CBAY

CBAY - Cymabay Therapeutics Inc Stock Price, Fair Value and News

32.48USD Market Closed

Market Summary

CBAY
USD32.48
Market Closed

CBAY Stock Price

View Fullscreen

CBAY RSI Chart

CBAY Valuation

Market Cap

3.7B

Price/Earnings (Trailing)

-35.36

Price/Sales (Trailing)

119.92

Price/Free Cashflow

-51.06

CBAY Price/Sales (Trailing)

CBAY Profitability

Return on Equity

-36.05%

Return on Assets

-24.24%

Free Cashflow Yield

-1.96%

CBAY Fundamentals

CBAY Revenue

Revenue (TTM)

31.1M

Rev. Growth (Yr)

-99.79%

Rev. Growth (Qtr)

-100%

CBAY Earnings

Earnings (TTM)

-105.4M

Earnings Growth (Yr)

-57.33%

Earnings Growth (Qtr)

-23.67%

Breaking Down CBAY Revenue

Last 7 days

0.1%

Last 30 days

0.9%

Last 90 days

40.7%

Trailing 12 Months

255.0%

How does CBAY drawdown profile look like?

CBAY Financial Health

Current Ratio

10.96

CBAY Investor Care

Shares Dilution (1Y)

35.48%

Diluted EPS (TTM)

-0.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202300031.1M
20220000
20210000
20175.4M7.7M4.8M10.0M
201212.1M9.1M6.1M3.0M
201100015.1M
2010000800.0K

Tracking the Latest Insider Buys and Sells of Cymabay Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 22, 2024
shantharam harish
back to issuer
-
-
-20,125
chief financial officer
Mar 22, 2024
wills robert james
back to issuer
-
-
-30,000
-
Mar 22, 2024
mcwherter charles
back to issuer
-
-
-46,938
president of r&d
Mar 22, 2024
quinlan paul t
back to issuer
-
-
-70,262
general counsel
Mar 22, 2024
emster kurt von
back to issuer
-
-
-90,000
-
Mar 22, 2024
shah sujal
back to issuer
-
-
-406,670
chief executive officer
Mar 22, 2024
dickinson klara
back to issuer
-
-
-21,000
chief regulatory officer
Mar 13, 2024
shah sujal
acquired
655,959
4.7151
139,119
chief executive officer
Mar 13, 2024
quinlan paul t
acquired
329,991
7.89
41,824
general counsel
Feb 12, 2024
dorling janet
acquired
27,780
4.63
6,000
-

1–10 of 50

Which funds bought or sold CBAY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
Fortitude Family Office, LLC
sold off
-100
-1,134
-
-%
Apr 05, 2024
GAMMA Investing LLC
sold off
-100
-5,172
-
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
1,833
186,881
193,188
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
new
-
1,062,900
1,062,900
-%
Mar 11, 2024
VANGUARD GROUP INC
added
9.72
63,254,700
148,951,000
-%
Mar 04, 2024
TUCKER ASSET MANAGEMENT LLC
new
-
88,551
88,551
0.02%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
124
21,435,000
29,795,900
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
14.94
599,161
1,329,050
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
reduced
-0.46
34,772,400
95,056,300
2.12%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-243,000
-
-%

1–10 of 36

Are Funds Buying or Selling CBAY?

Are funds buying CBAY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CBAY
No. of Funds

Unveiling Cymabay Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
janus henderson group plc
5.4%
6,103,797
SC 13G
Feb 14, 2024
commodore capital lp
0.0%
0
SC 13G/A
Feb 14, 2024
perceptive advisors llc
3.5%
4,024,400
SC 13G/A
Feb 14, 2024
avoro capital advisors llc
9.99%
16,337,739
SC 13G/A
Feb 13, 2024
tcg crossover gp i, llc
0%
0
SC 13G/A
Feb 13, 2024
vanguard group inc
5.56%
6,306,149
SC 13G
Jan 25, 2024
blackrock inc.
8.5%
9,610,239
SC 13G
Sep 22, 2023
ra capital management, l.p.
6.2%
6,940,000
SC 13G
Sep 11, 2023
adage capital partners gp, l.l.c.
3.76%
3,685,625
SC 13G
Mar 10, 2023
perceptive advisors llc
5.6%
5,278,962
SC 13G

Recent SEC filings of Cymabay Therapeutics Inc

View All Filings
Date Filed Form Type Document
Apr 01, 2024
15-12G
15-12G
Mar 28, 2024
EFFECT
EFFECT
Mar 28, 2024
EFFECT
EFFECT
Mar 28, 2024
EFFECT
EFFECT
Mar 28, 2024
EFFECT
EFFECT
Mar 28, 2024
EFFECT
EFFECT
Mar 22, 2024
SC TO-T/A
SC TO-T/A
Mar 22, 2024
SC 14D9/A
SC 14D9/A
Mar 22, 2024
S-8 POS
Employee Benefits Plan
Mar 22, 2024
S-8 POS
Employee Benefits Plan

Peers (Alternatives to Cymabay Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

Cymabay Therapeutics Inc News

Latest updates
Defense World11 Apr 202407:05 am
The Wall Street Journal2 months ago
The Motley Fool7 months ago

Cymabay Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22022Q42022Q42022Q32022Q22022Q12021Q42017Q42017Q32017Q22017Q12012Q42012Q32012Q22012Q12011Q42010Q4
Revenue-57.00-31,01627,32923,64219,95516,26812,5818,8945,207--4,79313.002,913----
Operating Expenses32.1%42,55532,20731,11523,477--23,76924,50224,509----------
  S&GA Expenses61.7%19,80612,24511,5787,247--5,8786,0876,104----------
  R&D Expenses14.0%22,74919,96219,53716,230--17,89118,41518,405----------
Interest Expenses4.9%5,0814,8434,6184,075--3,6483,3652,061234258283305------
Net Income-23.7%-41,902-33,882-808-26,633---27,094-27,769-26,543----------
Net Income Margin-Infinity%-3.39*--8.07*-10.60*-10.59*-10.41*-10.41*-10.02*-9.00*----------
Free Cashflow-5.4%-27,560-26,151-25,501-18,769-17,533-22,564-22,564-25,362-14,243----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-3.6%435451227245142159178201202123117137154168177189206232253274187
  Current Assets-9.8%404448224243138155167192191120114133152166174186203228250270182
    Cash Equivalents-24.5%20727435.0059.0020.0031.0053.0074.0012669.0033.0043.0028.0047.0096.0057.0025.0043.0028.0012649.00
  Net PPE2.6%0.000.001.001.001.001.001.001.001.001.002.002.002.002.002.002.002.003.003.003.003.00
Liabilities14.1%14212511814110699.0095.0093.0069.0036.0010.009.0011.0012.0011.0014.0019.0019.0017.0017.0016.00
  Current Liabilities87.3%37.0020.0018.0047.0015.0013.0013.0014.0018.0012.009.008.0010.0010.009.0012.0018.0017.0015.0014.0014.00
Shareholder's Equity-10.4%29232610810436.0060.0082.0010713387.00107128143157166175186213236258170
  Retained Earnings-4.5%-978-936-902-901-872-846-821-794-766-740-717-694-676-661-649-638-625-596-570-546-523
  Additional Paid-In Capital0.6%1,2701,2631,0111,006909907905902900827825822820818815814812809806804694
Shares Outstanding0.5%11411398.0097.0085.0088.0088.0088.0071.0069.0069.0069.00---------
Float---955---218---298---238---488--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-4.7%-27,380-26,151-25,4316,431-18,756-17,522-22,440-25,362-14,243-15,413-19,214-20,561-14,816-7,452-7,749-14,708-28,136-23,127-24,254-22,394-19,595
  Share Based Compensation25.4%4,6693,7243,3503,4872,3612,3502,3922,4142,3852,5492,5572,5051,8112,5529631,9982,0752,8652,2762,3421,738
Cashflow From Investing-372.3%-42,10715,461719-60,6428,356-4,5491,198-50,990-24,07728,2938,67935,694-4,349-41,32646,99946,6339,26138,508-73,072-9,04426,771
Cashflow From Financing-98.9%2,729248,9231,05093,070-9.00-24,54195,16323,186106-85.00-7.00-282--167108,01724.00

CBAY Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Collaboration revenue$ 31,073$ 0$ 0
Operating expenses:   
Research and development80,79967,99564,542
General and administrative51,95325,11623,040
Total operating expenses132,75293,11187,582
Loss from operations(101,679)(93,111)(87,582)
Other income (expense), net:   
Interest income13,4902,017167
Interest expense(18,945)(14,907)(2,583)
Other income1,76400
Total other income (expense), net(3,691)(12,890)(2,416)
Net loss(105,370)(106,001)(89,998)
Other comprehensive (loss) income:   
Unrealized gain (loss) on marketable securities, net of tax470(313)(21)
Total other comprehensive income (loss)470(313)(21)
Comprehensive loss$ (104,900)$ (106,314)$ (90,019)
Basic net loss per common share$ (0.99)$ (1.21)$ (1.27)
Diluted net loss per common share$ (0.99)$ (1.21)$ (1.27)
Weighted average common shares outstanding used to calculate basic net loss per common share106,204,27387,804,06371,055,331
Weighted average common shares outstanding used to calculate diluted net loss per common share106,204,27387,804,06371,055,331

CBAY Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 206,535$ 20,291
Marketable securities187,720115,194
Prepaid expenses and other current assets9,5472,588
Total current assets403,802138,073
Non-current marketable securities21,9320
Property and equipment, net465701
Right-of-use assets5,260169
Other assets3,2272,909
Total assets434,686141,852
Current liabilities:  
Accounts payable3,8281,096
Accrued research and development expenses5,6336,530
Development financing liability - current portion10,0000
Deferred collaboration revenue - current portion1,6890
Other accrued liabilities15,6937,815
Total current liabilities36,84315,441
Development financing liability - non-current portion99,17290,227
Deferred collaboration revenue - non-current portion1,1000
Lease liabilities - non-current portion5,31530
Total liabilities142,430105,698
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 200,000,000 shares authorized; 113,864,976 and 84,681,063 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively118
Additional paid-in capital1,270,328909,329
Accumulated other comprehensive income (loss)144(326)
Accumulated deficit(978,227)(872,857)
Total stockholders' equity292,25636,154
Total liabilities and stockholders' equity$ 434,686$ 141,852
CBAY
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
 CEO
 WEBSITEcymabay.com
 INDUSTRYBiotechnology
 EMPLOYEES60

Cymabay Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Cymabay Therapeutics Inc? What does CBAY stand for in stocks?

CBAY is the stock ticker symbol of Cymabay Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cymabay Therapeutics Inc (CBAY)?

As of Mon Mar 25 2024, market cap of Cymabay Therapeutics Inc is 3.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CBAY stock?

You can check CBAY's fair value in chart for subscribers.

What is the fair value of CBAY stock?

You can check CBAY's fair value in chart for subscribers. The fair value of Cymabay Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cymabay Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CBAY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cymabay Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CBAY is over valued or under valued. Whether Cymabay Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cymabay Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CBAY.

What is Cymabay Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Mar 25 2024, CBAY's PE ratio (Price to Earnings) is -35.36 and Price to Sales (PS) ratio is 119.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CBAY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cymabay Therapeutics Inc's stock?

In the past 10 years, Cymabay Therapeutics Inc has provided 0.15 (multiply by 100 for percentage) rate of return.